IL233557A0 - Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed - Google Patents
Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failedInfo
- Publication number
- IL233557A0 IL233557A0 IL233557A IL23355714A IL233557A0 IL 233557 A0 IL233557 A0 IL 233557A0 IL 233557 A IL233557 A IL 233557A IL 23355714 A IL23355714 A IL 23355714A IL 233557 A0 IL233557 A0 IL 233557A0
- Authority
- IL
- Israel
- Prior art keywords
- laquinimod
- failed
- disease patients
- line anti
- treating crohn
- Prior art date
Links
- 208000011231 Crohn disease Diseases 0.000 title 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595006P | 2012-02-03 | 2012-02-03 | |
| PCT/US2013/024356 WO2013116657A1 (en) | 2012-02-03 | 2013-02-01 | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233557A0 true IL233557A0 (en) | 2014-08-31 |
Family
ID=48903432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233557A IL233557A0 (en) | 2012-02-03 | 2014-07-08 | Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9161935B2 (enExample) |
| EP (1) | EP2811832A4 (enExample) |
| JP (2) | JP2015505564A (enExample) |
| KR (1) | KR20140138694A (enExample) |
| CN (2) | CN104093310A (enExample) |
| AR (1) | AR089862A1 (enExample) |
| AU (2) | AU2013214909A1 (enExample) |
| BR (1) | BR112014018485A8 (enExample) |
| CA (1) | CA2862865A1 (enExample) |
| EA (1) | EA201491460A1 (enExample) |
| HK (1) | HK1202776A1 (enExample) |
| IL (1) | IL233557A0 (enExample) |
| MX (1) | MX2014009373A (enExample) |
| SG (1) | SG11201404214QA (enExample) |
| TW (1) | TW201345527A (enExample) |
| WO (1) | WO2013116657A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
| JP2014530821A (ja) | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
| EP3225617A1 (en) | 2012-02-16 | 2017-10-04 | Teva Pharmaceutical Industries Ltd | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| HK1220444A1 (zh) | 2013-03-14 | 2017-05-05 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德钠晶体和用於制造它们的改进方法 |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| KR102883123B1 (ko) | 2015-06-22 | 2025-11-10 | 아레나 파마슈티칼스, 인크. | Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염 |
| CA2998349A1 (en) * | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| ES2981521T3 (es) | 2017-02-16 | 2024-10-09 | Arena Pharm Inc | Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN118649163A (zh) * | 2018-11-30 | 2024-09-17 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病况的方法 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| GB9726339D0 (en) | 1997-12-13 | 1998-02-11 | Zeneca Ltd | Human-derived tissue-specific potassium channel |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| RS51019B (sr) | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
| EP1365794A2 (en) | 2000-07-21 | 2003-12-03 | Lue, Tom | Prevention and treatment of sexual arousal disorders |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| CA2490043A1 (en) * | 2002-06-25 | 2003-12-31 | Merck Frosst Canada & Co. | 8-(biaryl) quinoline pde4 inhibitors |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| CA2528723A1 (en) | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| JP2007531735A (ja) | 2004-04-01 | 2007-11-08 | エラン ファーマシューティカルズ，インコーポレイテッド | ステロイド節約剤および該節約剤を使用する方法 |
| EP1796710A4 (en) | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| CA2595159A1 (en) | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| WO2006129178A1 (en) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| NZ597082A (en) | 2005-10-13 | 2013-11-29 | Human Genome Sciences Inc | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| HRP20141160T1 (hr) | 2005-10-19 | 2015-01-16 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju |
| KR20080064880A (ko) | 2005-10-26 | 2008-07-09 | 라보라뚜와르 세로노 에스. 에이. | 술폰아미드 유도체 및 금속단백분해효소를 조정하기 위한그것의 용도 |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| EP4276469A3 (en) | 2006-02-28 | 2024-01-17 | Biogen MA Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| AU2007224228B2 (en) | 2006-03-03 | 2013-09-19 | Biogen Ma Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| WO2007109052A2 (en) | 2006-03-16 | 2007-09-27 | Genentech, Inc. | Methods of treating lupus using cd4 antibodies |
| EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| ES2377149T3 (es) | 2006-06-12 | 2012-03-22 | Teva Pharmaceutical Industries Limited | Preparaciones de laquinimod estables |
| MX2009000645A (es) | 2006-07-17 | 2009-03-06 | Novartis Ag | Derivados de sulfonilaminocarbonilo de amidas de acido biliar para utilizarse en la forma de inmunomoduladores. |
| EP1886996A1 (en) | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| EP2056818B1 (en) | 2006-08-11 | 2011-05-25 | The Johns Hopkins University | Compositions and methods for neuroprotection |
| SI2056807T1 (sl) | 2006-08-17 | 2012-12-31 | University Of Chicago | Zdravljenje vnetnih bolezni |
| US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
| PT2187882E (pt) | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| WO2009053070A1 (en) | 2007-10-23 | 2009-04-30 | Schwarz Pharma Ag | Compounds for treating demyelination conditions |
| SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| KR20110048571A (ko) | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| PT2442651E (pt) | 2009-06-19 | 2015-10-22 | Teva Pharma | Tratamento da esclerose múltipla com laquinimod |
| AU2010276748A1 (en) | 2009-07-30 | 2012-03-15 | Teva Pharmaceutical Industries Ltd. | Treatment of Crohn's disease with laquinimod |
| HUE029983T2 (en) | 2009-08-10 | 2017-04-28 | Teva Pharma | Treatment of BDNF-related diseases with laquinimod |
| DE102010026879A1 (de) * | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| KR20130036217A (ko) | 2010-03-03 | 2013-04-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 관절염의 치료 |
| US8501766B2 (en) | 2010-03-03 | 2013-08-06 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| KR20130006640A (ko) | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| WO2012006544A1 (en) | 2010-07-09 | 2012-01-12 | Teva Pharmaceutical Industries Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| EP2648732A4 (en) | 2010-12-07 | 2014-04-30 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS |
| ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| US20130028866A1 (en) | 2011-07-28 | 2013-01-31 | Yossi Gilgun | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| CN103781354A (zh) | 2011-07-28 | 2014-05-07 | 泰华制药工业有限公司 | 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症 |
| JP2014530821A (ja) | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
| EP3225617A1 (en) | 2012-02-16 | 2017-10-04 | Teva Pharmaceutical Industries Ltd | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201804997A (zh) | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015533163A (ja) | 2012-10-12 | 2015-11-19 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症における視床損傷を低減するためのラキニモド |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| HK1218254A1 (zh) | 2013-02-15 | 2017-02-10 | Teva Pharmaceutical Industries Ltd. | 用拉喹莫德治疗多发性硬化症 |
| MX2015010967A (es) | 2013-03-14 | 2015-10-26 | Teva Pharma | Formulaciones transdermicas de laquinimod. |
| HK1220444A1 (zh) | 2013-03-14 | 2017-05-05 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德钠晶体和用於制造它们的改进方法 |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
-
2013
- 2013-02-01 JP JP2014555758A patent/JP2015505564A/ja not_active Withdrawn
- 2013-02-01 CA CA2862865A patent/CA2862865A1/en not_active Abandoned
- 2013-02-01 AU AU2013214909A patent/AU2013214909A1/en not_active Abandoned
- 2013-02-01 EA EA201491460A patent/EA201491460A1/ru unknown
- 2013-02-01 TW TW102104087A patent/TW201345527A/zh unknown
- 2013-02-01 WO PCT/US2013/024356 patent/WO2013116657A1/en not_active Ceased
- 2013-02-01 BR BR112014018485A patent/BR112014018485A8/pt not_active IP Right Cessation
- 2013-02-01 AR ARP130100296A patent/AR089862A1/es unknown
- 2013-02-01 HK HK15103524.2A patent/HK1202776A1/xx unknown
- 2013-02-01 CN CN201380007766.6A patent/CN104093310A/zh active Pending
- 2013-02-01 KR KR1020147024856A patent/KR20140138694A/ko not_active Withdrawn
- 2013-02-01 MX MX2014009373A patent/MX2014009373A/es unknown
- 2013-02-01 CN CN201610357641.1A patent/CN106063787A/zh active Pending
- 2013-02-01 EP EP13744015.2A patent/EP2811832A4/en not_active Withdrawn
- 2013-02-01 SG SG11201404214QA patent/SG11201404214QA/en unknown
- 2013-02-01 US US13/757,004 patent/US9161935B2/en active Active
-
2014
- 2014-07-08 IL IL233557A patent/IL233557A0/en unknown
-
2015
- 2015-08-25 US US14/835,123 patent/US20150359788A1/en not_active Abandoned
-
2017
- 2017-01-24 AU AU2017200472A patent/AU2017200472A1/en not_active Abandoned
- 2017-05-26 JP JP2017104049A patent/JP2017200926A/ja not_active Withdrawn
- 2017-06-26 US US15/633,132 patent/US20170290822A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140138694A (ko) | 2014-12-04 |
| JP2015505564A (ja) | 2015-02-23 |
| AR089862A1 (es) | 2014-09-24 |
| AU2017200472A1 (en) | 2017-02-09 |
| WO2013116657A1 (en) | 2013-08-08 |
| EP2811832A1 (en) | 2014-12-17 |
| HK1202776A1 (en) | 2015-10-09 |
| AU2013214909A1 (en) | 2014-09-18 |
| JP2017200926A (ja) | 2017-11-09 |
| SG11201404214QA (en) | 2014-08-28 |
| CN106063787A (zh) | 2016-11-02 |
| BR112014018485A8 (pt) | 2017-07-11 |
| US20170290822A1 (en) | 2017-10-12 |
| BR112014018485A2 (enExample) | 2017-06-20 |
| US20130203807A1 (en) | 2013-08-08 |
| CN104093310A (zh) | 2014-10-08 |
| CA2862865A1 (en) | 2013-08-08 |
| MX2014009373A (es) | 2014-08-27 |
| EP2811832A4 (en) | 2015-09-23 |
| US9161935B2 (en) | 2015-10-20 |
| TW201345527A (zh) | 2013-11-16 |
| US20150359788A1 (en) | 2015-12-17 |
| EA201491460A1 (ru) | 2015-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233557A0 (en) | Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed | |
| IL265774B (en) | Diagnosis, prevention and treatment of joint diseases | |
| IL239488A0 (en) | A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial | |
| IL249991A0 (en) | Methods of treating sick children by dexmedetomidine | |
| SG11201501075RA (en) | Medical devices for blood reflux prevention and methods of use | |
| IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| ZA201406916B (en) | New therapeutic approaches for treating parkinson's disease | |
| PL2701645T3 (pl) | Urządzenie do leczenia i/lub zapobiegania chorobom rogówki | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
| IL232434A0 (en) | Medicine for medical treatment and/or improvement of sepsis | |
| IL233572B (en) | A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease | |
| SG11201502210VA (en) | Treatment of mild and moderate alzheimer's disease | |
| GB2499687B (en) | Medical device for the treatment of a patient | |
| IL234093A0 (en) | Preparations and dosages for oral administration and their uses for the treatment of Gaucher's disease | |
| PL2861568T3 (pl) | Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca | |
| SG11201406093VA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
| EP3094330A4 (en) | Treatment of crohn's disease using low doses of laquinimod | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| GB201113718D0 (en) | Treatment of Dupuytren's Disease |